Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:UTHR - United Therapeutics Stock Price, Forecast & News

$90.87
-1.57 (-1.70 %)
(As of 01/24/2020 01:01 AM ET)
Today's Range
$90.24
Now: $90.87
$92.90
50-Day Range
$85.67
MA: $89.84
$94.14
52-Week Range
$74.31
Now: $90.87
$128.94
Volume302,175 shs
Average Volume411,092 shs
Market Capitalization$3.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$14.18 per share
Book Value$63.98 per share

Profitability

Net Income$589.20 million

Miscellaneous

Employees860
Market Cap$3.99 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.34 by $0.82. The biotechnology company earned $401.50 million during the quarter, compared to the consensus estimate of $342.28 million. United Therapeutics had a negative return on equity of 3.54% and a negative net margin of 6.04%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period last year, the business posted $3.98 EPS. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

10 Wall Street analysts have issued twelve-month price objectives for United Therapeutics' shares. Their forecasts range from $80.00 to $237.00. On average, they expect United Therapeutics' stock price to reach $117.30 in the next twelve months. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

Has United Therapeutics been receiving favorable news coverage?

Press coverage about UTHR stock has been trending somewhat negative on Thursday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. United Therapeutics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for United Therapeutics.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), Celgene (CELG), General Electric (GE), Biogen (BIIB), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), AT&T (T), Netflix (NFLX), Nektar Therapeutics (NKTR) and Allergan (AGN).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Greylin Investment Mangement Inc. (0.36%), DNB Asset Management AS (0.27%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.02%), Cardinal Capital Management (0.01%) and Alpha Windward LLC (0.01%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Greylin Investment Mangement Inc., Nisa Investment Advisors LLC, Wedbush Securities Inc. and State of Alaska Department of Revenue. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Which major investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Cardinal Capital Management, Alpine Global Management LLC, Alpha Windward LLC, Advisors Preferred LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $90.87.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $3.99 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com/.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  447 (Vote Outperform)
Underperform Votes:  607 (Vote Underperform)
Total Votes:  1,054
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel